Common Contracts

EX-10.76 7 dex1076.htm SUBLICENSE AGREEMENT Portions of this exhibit marked [*] are requested to be treated confidentially. Execution Version Dated September 29, 2010 Salix Pharmaceuticals, Inc. - and - - and - A general partnership of Craig Aronchick...

Sublicense Agreement • May 5th, 2020 • New York

• Contract Type
  Sublicense Agreement
• Filed
  May 5th, 2020
• Jurisdiction
  New York

THIS SUBLICENSE AGREEMENT (this “Agreement”) is made the 29th day of September, 2010 (the “Execution Date”), between SALIX PHARMACEUTICALS, INC., a California corporation (“Sublicensor”); CDC III, LLC, a Delaware limited liability company (“CDC III”); a general partnership of Craig Aronchick, William H. Lipshutz, and Scott H. Wright (the “General Partnership”; each of the General Partnership and CDC III, a “Licensor”, and together, the “Licensors”); and NOVEL LABORATORIES, INC., a Delaware corporation (“Sublicensee”). In this Agreement, Sublicensor, Sublicensee, CDC III and the General Partnership are referred to together as the “Parties” and each is referred to as a “Party.”

Dated September 29, 2010 Salix Pharmaceuticals, Inc. - and - - and - A general partnership of Craig Aronchick William H. Lipshutz and Scott H. Wright - and - Novel Laboratories, Inc. SUBLICENSE AGREEMENT (Osmoprep®)

Sublicense Agreement • November 9th, 2010 • Salix Pharmaceuticals LTD • Pharmaceutical preparations • New York

• Contract Type
  Sublicense Agreement
• Filed
  November 9th, 2010
• Company
  Salix Pharmaceuticals LTD
• Industry
  Pharmaceutical preparations
• Jurisdiction
  New York

THIS SUBLICENSE AGREEMENT (this “Agreement”) is made the 29th day of September, 2010 (the “Execution Date”), between SALIX PHARMACEUTICALS, INC., a California corporation (“Sublicensor”); CDC III, LLC, a Delaware limited liability company (“CDC III”); a general partnership of Craig Aronchick, William H. Lipshutz, and Scott H. Wright (the “General Partnership”; each of the General Partnership and CDC III, a “Licensor”, and together, the “Licensors”); and NOVEL LABORATORIES, INC., a Delaware corporation (“Sublicensee”). In this Agreement, Sublicensor, Sublicensee, CDC III and the General Partnership are referred to together as the “Parties” and each is referred to as a “Party.”